Result dissemination is important for scientific progress; however, 25% to 50% of clinical trials are not published.
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Subcategories were subsequently assigned and potential publications were identified. A systematic 3-step process similar to previous studies 1 was used to verify publication status, including (1) identification of relevant publications via the associated ClinicalTrials.gov webpage; (2) search of SCOPUS (Elsevier) with the specified terms for the [intervention] and [condition treated] and [primary investigator]; and (3) comparison of trial characteristics against potential publications. All statistical tests were conducted using SPSS, version 19 software (SPSS Inc), including a 2-tailed (P < .05) repeated measures analysis of variance to compare time to publication across subcategories.
Results | A total of 2072 trials were identified on Clinical Trials.gov using the specified criteria (Table) . mary end point. The mean (SD) time to publication was 26.4 (15.2) months for all trials, with a significant difference among subcategories (Figure) (F 9 = 2.793; P = .003). Studies of vascular neurology had the fastest time to publication, with a median of 18 (13.8) months, which was more rapid than those of behavioral/neuropsychiatry (P = .002; SD, 16.5 months), pain medicine (P = .03; SD, 15.6 months), and epilepsy (P = .01; SD, 17.0 months) on follow-up testing.
Discussion | We found that 48% of neurology trials (990 of 2072) were published in a scientific journal at a median (SD) of 25 (15.2) months, which is comparable to previous work. 4,5 However, our review suggested lower rates of dissemination through ClinicalTrials.gov. Among subcategories, pain medicine composed the largest percentage, likely due to overlap between multiple specialties interested in pain alleviation. Neuro-oncology had unique characteristics, including a higher proportion of NIH funding, higher rates of overall publication, and shorter median time to publication. The central driving factor may be NIH funding, which was associated with a significantly higher publication rate. Vascular neurology trials had the fastest time to publication, which could stem from the prevalence of vascular niche journals, allowing for easier dissemination. An important limitation of this analysis is the finite search criteria and databases used to identify publications; however, given that our rates mirror previous work, these errors were likely minimized. This analysis suggests that neurology trials face similar dissemination problems as other clinical trials. Areas of improvement include reporting raw results through ClinicalTrials.gov, achieving other means of data sharing between institutions, and avoiding the propensity to publish only studies achieving their primary outcome. Signs of encouragement include more journals requiring trial registration numbers, which promotes research tracking. In addition, institutes like our own are creating data-sharing platforms (eg, Yale University Open Data Access). While we found differences among subcategories, these may stem from underlying funding sources. Overall, these results reemphasize the necessary steps required for the timely dissemination of research results. 
